LSV Asset Management Has $2.82 Million Holdings in Embecta Corp. (NASDAQ:EMBC)

LSV Asset Management trimmed its holdings in shares of Embecta Corp. (NASDAQ:EMBC - Free Report) by 33.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 136,400 shares of the company's stock after selling 68,800 shares during the period. LSV Asset Management owned about 0.23% of Embecta worth $2,817,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of EMBC. Garden State Investment Advisory Services LLC bought a new stake in shares of Embecta in the 3rd quarter valued at about $438,000. Barclays PLC lifted its position in Embecta by 41.1% during the third quarter. Barclays PLC now owns 97,930 shares of the company's stock worth $1,381,000 after acquiring an additional 28,523 shares during the last quarter. Jane Street Group LLC grew its position in shares of Embecta by 156.1% in the third quarter. Jane Street Group LLC now owns 176,487 shares of the company's stock valued at $2,488,000 after purchasing an additional 107,567 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Embecta by 3.4% in the third quarter. Geode Capital Management LLC now owns 1,387,273 shares of the company's stock valued at $19,564,000 after purchasing an additional 45,228 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. acquired a new stake in Embecta during the 4th quarter worth approximately $209,000. Institutional investors own 93.83% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Mizuho initiated coverage on Embecta in a report on Thursday, April 10th. They issued a "neutral" rating and a $15.00 price objective on the stock.

Embecta Stock Performance

EMBC remained flat at $11.34 during trading on Friday. 444,431 shares of the company's stock traded hands, compared to its average volume of 456,171. The business's fifty day moving average is $13.12 and its 200 day moving average is $15.88. Embecta Corp. has a 1-year low of $10.00 and a 1-year high of $21.48. The firm has a market cap of $659.24 million, a P/E ratio of 11.34, a price-to-earnings-growth ratio of 0.78 and a beta of 1.23.

Embecta (NASDAQ:EMBC - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.20. Embecta had a net margin of 5.25% and a negative return on equity of 19.22%. On average, analysts forecast that Embecta Corp. will post 2.85 EPS for the current year.

Embecta Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, March 14th. Shareholders of record on Friday, February 28th were issued a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a yield of 5.29%. The ex-dividend date of this dividend was Friday, February 28th. Embecta's payout ratio is presently 60.00%.

Insider Buying and Selling at Embecta

In other news, Director Milton Mayo Morris sold 3,100 shares of the company's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $16.38, for a total value of $50,778.00. Following the sale, the director now directly owns 36,133 shares of the company's stock, valued at approximately $591,858.54. This represents a 7.90 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.42% of the company's stock.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.